Montelukast in children with allergic rhinitis amid COVID‐19 pandemic

Kow, Chia Siang; Hasan, Syed Shahzad

doi:10.1111/apa.15491

Cited by 6 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, these authors also underline how the failure to control rhinitis with the classic symptoms, in particular sneezing, can favor the transmission of the virus. Some authors also suggested that montelukast could be also considered in pediatric age to treat AR during the COVID-19 pandemic, considering the potential anti-inflammatory action of this medication (51).…”

Section: Younger Age And/or Absence Of Comorbiditiesmentioning

confidence: 99%

Allergic rhinitis and COVID-19: friends or foes?

Gani¹,

Cottini²,

Landi

et al. 2022

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide.In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.AR patients seem to be protected from COVID 19 infection. Even if data about the influence of AR on the severity of COVID-19 disease are still not conclusive, it seems that being an AR patient does not increase the risk of poor COVID-19 prognoses. The clinical manifestation of AR can be distinguished by COVID-19 symptoms. Treating AR adequately is also strongly recommended, especially during pandemic.

show abstract

Section: Younger Age And/or Absence Of Comorbiditiesmentioning

confidence: 99%

Allergic rhinitis and COVID-19: friends or foes?

Gani¹,

Cottini²,

Landi

et al. 2022

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

“…During the COVID-19 pandemic, MTK was used as an off-label drug in the prevention and treatment of pulmonary distress in patients infected with SARS-CoV-2. Its properties as an anti-inflammatory drug allied to cardiovascular benefits on thrombosis and vascular damage, as well as the potential beneficial effects on brain functions, make this drug a good candidate against COVID-19 symptoms [196][197][198][199][200].…”

Section: Montelukast Repurposing Applicationsmentioning

confidence: 99%

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Marques

Justino

2022

Pharmaceuticals

View full text Add to dashboard Cite

Increasing environmental distress is associated with a growing asthma incidence; no treatments are available but montelukast (MTK)—an antagonist of the cysteinyl leukotrienes receptor 1—is widely used in the management of symptoms among adults and children. Recently, new molecular targets have been identified and MTK has been proposed for repurposing in other therapeutic applications, with several ongoing clinical trials. The proposed applications include neuroinflammation control, which could be explored in some neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (AD and PD). However, this drug has been associated with an increasing number of reported neuropsychiatric adverse drug reactions (ADRs). Besides, and despite being on the market since 1998, MTK metabolism is still poorly understood and the mechanisms underlying neuropsychiatric ADRs remain unknown. We review the role of MTK as a modulator of leukotriene pathways and systematize the current knowledge about MTK metabolism. Known toxic effects of MTK are discussed, and repurposing applications are presented comprehensively, with a focus on AD and PD.

show abstract

Section: Montelukast Repurposing Applicationsmentioning

confidence: 99%

Leukotrienes vs. Montelukast – Activity, Metabolism, and Toxicity Hints for Repurposing

Marques¹,

Marques²,

Justino³

2022

Preprint

View full text Add to dashboard Cite

Increasing environmental distress is associated with a growing asthma incidence and, with no treatments available, montelukast (MTK) – an antagonist of the cysteinyl leukotrienes receptor 1 – is widely used in the management of symptoms among adults and children. Recently, new molecular targets have been identified and MTK has been proposed for repurposing in other therapeutic applications, with several ongoing clinical trials. The proposed applications include neuroinflammation control, which could be explored in some neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (AD and PD). However, this drug has been associated with an increasing number of reported neuropsychiatric adverse drug reactions. Besides, and despite being on the market since 1998, MTK metabolism is still poorly understood and the mechanisms underlying neuropsychiatric ADRs remain unknown. We review the role of MTK as modulator of leukotriene pathways and systematize the knowledge about MTK metabolism. Known toxic effects of MTK are discussed, and repurposing applications are presented comprehensively, with a focus on AD and PD.

show abstract

Montelukast in children with allergic rhinitis amid COVID‐19 pandemic

Cited by 6 publications

References 3 publications

Allergic rhinitis and COVID-19: friends or foes?

Allergic rhinitis and COVID-19: friends or foes?

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Leukotrienes vs. Montelukast – Activity, Metabolism, and Toxicity Hints for Repurposing

Contact Info

Product

Resources

About